Roche sees 1st-half profit drop on franc strength; sales up

Drug maker Roche Holding AG says its first-half profit was weighed down by the surging Swiss franc and one-time effects, while solid sales of cancer treatments helped push revenue higher.

Roche, which reports earnings every six months, said Thursday that for the January-June period was 5.25 billion francs ($5.5 billion)—down 7 percent from 5.64 billion francs a year earlier.

Revenue rose 3 percent to 23.59 billion francs from 22.97 billion francs. Roche said it saw particularly strong increases in sales of breast cancer drugs.

Roche pointed to "the significant negative currency impact" as a factor in the drop in profit, along with factors such as the impact of recent acquisitions including that of InterMune, a developer of lung disease treatments.

Explore further

Swiss drug maker Roche posts 7 percent profit drop

© 2015 The Associated Press. All rights reserved.

Citation: Roche sees 1st-half profit drop on franc strength; sales up (2015, July 23) retrieved 28 September 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors